ASH 2023 | Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM
Maximilian Merz, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses a longitudinal study which used single-cell multi-omics to identify factors that predict responses to idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapies in patients with relapsed/refractory (R/R) multiple myeloma (MM). CAR-T cells which were not functional in the patient displayed activity when analyzed in vitro, suggesting a hypothesis that the environment surrounding CAR T-cells determines resistance. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Amgen, Takeda, BMS, Janssen, Stemline, Roche
